Table 3.
Length of Treatment in Provoked VTE Comparing 2008 to 2014 and 2015 to 2020
| Treatment length | Warfarin before 2015, N=246 | Warfarin after 2015 and DOAC, N=530 | P value |
|---|---|---|---|
| Length of treatment, d, median (25th–75th percentile) | 137 (92–220) | 180 (96–272) | 0.001 |
| Guideline‐appropriate length of treatment, ≥80 to ≤120 d, n (%) | 63 (25.6) | 120 (22.6) | 0.36 |
| Treatment >120 d, n (%) | 132 (53.7) | 350 (66) | 0.001 |
| Treatment <80 d, n (%) | 51 (20.7) | 60 (11.3) | <0.001 |
Data were obtained using a median 2‐sample test for length of treatment and χ2 test for the rest. DOAC indicates direct oral anticoagulant; and IQR, interquartile range.